Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer
The combination of pertuzumab and trastuzumab resulted in a clinical benefit rate (CBR) of 50% in patients with human epidermal growth factor receptor 2 (HER2) -positive breast cancer whose disease progressed during prior trastuzumab-based therapy. To define whether this previously observed encourag...
Uloženo v:
| Vydáno v: | Journal of clinical oncology Ročník 30; číslo 14; s. 1594 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
10.05.2012
|
| Témata: | |
| ISSN: | 1527-7755, 1527-7755 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | The combination of pertuzumab and trastuzumab resulted in a clinical benefit rate (CBR) of 50% in patients with human epidermal growth factor receptor 2 (HER2) -positive breast cancer whose disease progressed during prior trastuzumab-based therapy. To define whether this previously observed encouraging activity was a result of the combination of pertuzumab and trastuzumab or of pertuzumab alone, we recruited a third cohort of patients who received pertuzumab without trastuzumab. We then investigated the impact of reintroducing trastuzumab to patients whose disease progressed on pertuzumab monotherapy.
Twenty-nine patients with HER2-positive breast cancer whose disease progressed during prior trastuzumab-based therapy received pertuzumab (840 mg loading dose, then 420 mg every 3 weeks) until progressive disease or unacceptable toxicity. Seventeen patients with disease progression continued to receive pertuzumab (at the same dose), with the addition of trastuzumab (4 mg/kg loading dose and then 2 mg/kg weekly or 8 mg/kg loading dose and then 6 mg/kg every 3 weeks).
All 29 patients enrolled for pertuzumab monotherapy experienced disease progression. The objective response rate (ORR) and CBR were 3.4% and 10.3%, respectively, during pertuzumab monotherapy. With the addition of trastuzumab, the ORR and CBR were 17.6% and 41.2%, respectively. Progression-free survival was longer with combination therapy than pertuzumab monotherapy (17.4 v 7.1 weeks, respectively). Treatment was well tolerated with minimal cardiac dysfunction.
Although pertuzumab has some activity in patients with HER2-positive breast cancer that progressed during therapy with trastuzumab, the combination of pertuzumab and trastuzumab seems to be more active than monotherapy. |
|---|---|
| AbstractList | The combination of pertuzumab and trastuzumab resulted in a clinical benefit rate (CBR) of 50% in patients with human epidermal growth factor receptor 2 (HER2) -positive breast cancer whose disease progressed during prior trastuzumab-based therapy. To define whether this previously observed encouraging activity was a result of the combination of pertuzumab and trastuzumab or of pertuzumab alone, we recruited a third cohort of patients who received pertuzumab without trastuzumab. We then investigated the impact of reintroducing trastuzumab to patients whose disease progressed on pertuzumab monotherapy.
Twenty-nine patients with HER2-positive breast cancer whose disease progressed during prior trastuzumab-based therapy received pertuzumab (840 mg loading dose, then 420 mg every 3 weeks) until progressive disease or unacceptable toxicity. Seventeen patients with disease progression continued to receive pertuzumab (at the same dose), with the addition of trastuzumab (4 mg/kg loading dose and then 2 mg/kg weekly or 8 mg/kg loading dose and then 6 mg/kg every 3 weeks).
All 29 patients enrolled for pertuzumab monotherapy experienced disease progression. The objective response rate (ORR) and CBR were 3.4% and 10.3%, respectively, during pertuzumab monotherapy. With the addition of trastuzumab, the ORR and CBR were 17.6% and 41.2%, respectively. Progression-free survival was longer with combination therapy than pertuzumab monotherapy (17.4 v 7.1 weeks, respectively). Treatment was well tolerated with minimal cardiac dysfunction.
Although pertuzumab has some activity in patients with HER2-positive breast cancer that progressed during therapy with trastuzumab, the combination of pertuzumab and trastuzumab seems to be more active than monotherapy. The combination of pertuzumab and trastuzumab resulted in a clinical benefit rate (CBR) of 50% in patients with human epidermal growth factor receptor 2 (HER2) -positive breast cancer whose disease progressed during prior trastuzumab-based therapy. To define whether this previously observed encouraging activity was a result of the combination of pertuzumab and trastuzumab or of pertuzumab alone, we recruited a third cohort of patients who received pertuzumab without trastuzumab. We then investigated the impact of reintroducing trastuzumab to patients whose disease progressed on pertuzumab monotherapy.PURPOSEThe combination of pertuzumab and trastuzumab resulted in a clinical benefit rate (CBR) of 50% in patients with human epidermal growth factor receptor 2 (HER2) -positive breast cancer whose disease progressed during prior trastuzumab-based therapy. To define whether this previously observed encouraging activity was a result of the combination of pertuzumab and trastuzumab or of pertuzumab alone, we recruited a third cohort of patients who received pertuzumab without trastuzumab. We then investigated the impact of reintroducing trastuzumab to patients whose disease progressed on pertuzumab monotherapy.Twenty-nine patients with HER2-positive breast cancer whose disease progressed during prior trastuzumab-based therapy received pertuzumab (840 mg loading dose, then 420 mg every 3 weeks) until progressive disease or unacceptable toxicity. Seventeen patients with disease progression continued to receive pertuzumab (at the same dose), with the addition of trastuzumab (4 mg/kg loading dose and then 2 mg/kg weekly or 8 mg/kg loading dose and then 6 mg/kg every 3 weeks).PATIENTS AND METHODSTwenty-nine patients with HER2-positive breast cancer whose disease progressed during prior trastuzumab-based therapy received pertuzumab (840 mg loading dose, then 420 mg every 3 weeks) until progressive disease or unacceptable toxicity. Seventeen patients with disease progression continued to receive pertuzumab (at the same dose), with the addition of trastuzumab (4 mg/kg loading dose and then 2 mg/kg weekly or 8 mg/kg loading dose and then 6 mg/kg every 3 weeks).All 29 patients enrolled for pertuzumab monotherapy experienced disease progression. The objective response rate (ORR) and CBR were 3.4% and 10.3%, respectively, during pertuzumab monotherapy. With the addition of trastuzumab, the ORR and CBR were 17.6% and 41.2%, respectively. Progression-free survival was longer with combination therapy than pertuzumab monotherapy (17.4 v 7.1 weeks, respectively). Treatment was well tolerated with minimal cardiac dysfunction.RESULTSAll 29 patients enrolled for pertuzumab monotherapy experienced disease progression. The objective response rate (ORR) and CBR were 3.4% and 10.3%, respectively, during pertuzumab monotherapy. With the addition of trastuzumab, the ORR and CBR were 17.6% and 41.2%, respectively. Progression-free survival was longer with combination therapy than pertuzumab monotherapy (17.4 v 7.1 weeks, respectively). Treatment was well tolerated with minimal cardiac dysfunction.Although pertuzumab has some activity in patients with HER2-positive breast cancer that progressed during therapy with trastuzumab, the combination of pertuzumab and trastuzumab seems to be more active than monotherapy.CONCLUSIONAlthough pertuzumab has some activity in patients with HER2-positive breast cancer that progressed during therapy with trastuzumab, the combination of pertuzumab and trastuzumab seems to be more active than monotherapy. |
| Author | Conte, Pierfranco Dixon, Joanna Szado, Tania Servent, Veronique Gelmon, Karen Ross, Graham A Salvagni, Stefania Scaltriti, Maurizio Fumoleau, Pierre Albanell, Joan Bianchi, Giulia Valeria Lluch, Ana Verma, Shailendra Pivot, Xavier Baselga, José Gianni, Luca Cortés, Javier Petrella, Teresa M |
| Author_xml | – sequence: 1 givenname: Javier surname: Cortés fullname: Cortés, Javier organization: Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA – sequence: 2 givenname: Pierre surname: Fumoleau fullname: Fumoleau, Pierre – sequence: 3 givenname: Giulia Valeria surname: Bianchi fullname: Bianchi, Giulia Valeria – sequence: 4 givenname: Teresa M surname: Petrella fullname: Petrella, Teresa M – sequence: 5 givenname: Karen surname: Gelmon fullname: Gelmon, Karen – sequence: 6 givenname: Xavier surname: Pivot fullname: Pivot, Xavier – sequence: 7 givenname: Shailendra surname: Verma fullname: Verma, Shailendra – sequence: 8 givenname: Joan surname: Albanell fullname: Albanell, Joan – sequence: 9 givenname: Pierfranco surname: Conte fullname: Conte, Pierfranco – sequence: 10 givenname: Ana surname: Lluch fullname: Lluch, Ana – sequence: 11 givenname: Stefania surname: Salvagni fullname: Salvagni, Stefania – sequence: 12 givenname: Veronique surname: Servent fullname: Servent, Veronique – sequence: 13 givenname: Luca surname: Gianni fullname: Gianni, Luca – sequence: 14 givenname: Maurizio surname: Scaltriti fullname: Scaltriti, Maurizio – sequence: 15 givenname: Graham A surname: Ross fullname: Ross, Graham A – sequence: 16 givenname: Joanna surname: Dixon fullname: Dixon, Joanna – sequence: 17 givenname: Tania surname: Szado fullname: Szado, Tania – sequence: 18 givenname: José surname: Baselga fullname: Baselga, José |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22393084$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNUctOBCEQJEbjY_XuyXD0MivDMI_1ZjY-Y6IHPW8a6HExMzACo1k_1a-R1TXxRFFNVZGuA7JtnUVCjnM2zTljZ3fzhylneT4t6qngrN4i-3nJ66yuy3L7H94jByG8MpaLpih3yR7nxaxgjdgnX4_o4_g59iBp76yLS_QwrCi0ET2NHsJmmkkIqBODEHu0kYLVNIwy4Nu4vno0NnqnRxWNs9S1_8XnFBL9buLqRxZdl1Kk6daEsXSAaJJHoB8mLinod7AqZS2T1FIcjEbfQ0dfvPtI8zZ5OZ8CFQ5rwLPBBZPskcr0uxCpWuv9IdlpoQt4tDkn5Pnq8ml-k90_XN_OL-4zJQSLGUrAJqEZa1muStSVrgpd8tlMsLIum7TDooWqrYRkquWopAAlVVVrVssCNZ-Q01_fwbu0ixAXvQkKuw4sujEs8lRQIwqW2piQk83TUfaoF4M3PfjV4q8P_g0fPJd2 |
| CitedBy_id | crossref_primary_10_1371_journal_pone_0216095 crossref_primary_10_1007_s12325_013_0043_2 crossref_primary_10_1200_EDBK_281107 crossref_primary_10_3810_hp_2012_10_997 crossref_primary_10_1016_S0140_6736_16_31891_8 crossref_primary_10_1002_phar_1338 crossref_primary_10_1371_journal_pone_0106448 crossref_primary_10_1158_2159_8290_CD_13_0063 crossref_primary_10_1097_CCO_0000000000000175 crossref_primary_10_1200_JCO_2011_40_1463 crossref_primary_10_1007_s00280_016_3214_4 crossref_primary_10_3892_etm_2017_4873 crossref_primary_10_1158_1078_0432_CCR_18_3502 crossref_primary_10_1146_annurev_med_042513_015127 crossref_primary_10_1016_j_clbc_2013_05_002 crossref_primary_10_1016_j_jaccao_2022_09_007 crossref_primary_10_1517_14712598_2013_783007 crossref_primary_10_1310_hpj4712_920 crossref_primary_10_1080_14737140_2021_1894932 crossref_primary_10_1159_000506824 crossref_primary_10_1093_annonc_mdt217 crossref_primary_10_1002_onco_13860 crossref_primary_10_1097_CJI_0000000000000152 crossref_primary_10_1158_0008_5472_CAN_13_0657 crossref_primary_10_1007_s12609_013_0121_0 crossref_primary_10_1093_annonc_mdt182 crossref_primary_10_1517_17425255_2015_1080687 crossref_primary_10_1111_ajco_12207 crossref_primary_10_1590_0001_3765201620150178 crossref_primary_10_1007_s11912_015_0471_z crossref_primary_10_2217_fon_15_7 crossref_primary_10_1007_s12609_015_0191_2 crossref_primary_10_1007_s00280_014_2560_3 crossref_primary_10_3389_fonc_2022_855308 crossref_primary_10_1007_s10549_021_06329_x crossref_primary_10_1016_S1470_2045_17_30021_9 crossref_primary_10_1038_bjc_2014_388 crossref_primary_10_1038_s41598_018_27886_0 crossref_primary_10_1007_s40495_015_0040_z crossref_primary_10_1016_j_critrevonc_2015_02_002 crossref_primary_10_3389_fonc_2018_00089 crossref_primary_10_1001_jamanetworkopen_2019_16211 crossref_primary_10_1007_s40267_015_0267_0 crossref_primary_10_1002_cncr_28815 crossref_primary_10_1016_S1470_2045_12_70367_4 crossref_primary_10_1093_annonc_mdu385 crossref_primary_10_1097_01_NURSE_0000426621_59131_e5 crossref_primary_10_1002_1878_0261_12414 crossref_primary_10_1080_14737140_2019_1596805 crossref_primary_10_1007_s40487_021_00178_w crossref_primary_10_1684_bdc_2014_1940 crossref_primary_10_1586_14737140_2013_814419 crossref_primary_10_4161_2162402X_2014_994391 crossref_primary_10_1056_NEJMe1706150 crossref_primary_10_1093_jncimonographs_lgad011 crossref_primary_10_1186_s12967_025_06126_w crossref_primary_10_1158_1078_0432_CCR_23_3839 crossref_primary_10_1007_s11912_013_0359_8 crossref_primary_10_1186_s40164_017_0091_4 crossref_primary_10_1007_s10269_015_2534_z crossref_primary_10_1016_j_annonc_2021_03_209 crossref_primary_10_1016_j_breast_2012_09_008 crossref_primary_10_5812_iranjradiol_96419 crossref_primary_10_1517_14740338_2016_1167185 crossref_primary_10_1016_j_ctrv_2014_07_002 crossref_primary_10_1186_s40425_015_0084_y crossref_primary_10_1517_14712598_2013_789497 crossref_primary_10_3390_pharmaceutics14071338 crossref_primary_10_1016_j_soc_2013_06_010 crossref_primary_10_1517_17425255_2015_1078311 crossref_primary_10_1007_s40265_013_0109_0 crossref_primary_10_1080_14656566_2017_1409206 crossref_primary_10_1007_s10269_015_2484_5 crossref_primary_10_2146_ajhp120735 crossref_primary_10_1111_cts_70313 crossref_primary_10_1016_j_clbc_2021_02_001 crossref_primary_10_1016_j_annonc_2021_09_019 crossref_primary_10_1080_14740338_2017_1351541 crossref_primary_10_7759_cureus_21748 crossref_primary_10_1016_j_jval_2018_11_014 crossref_primary_10_5497_wjp_v3_i4_72 crossref_primary_10_1007_s12609_014_0155_y crossref_primary_10_1155_2015_428169 crossref_primary_10_3390_cancers11121822 crossref_primary_10_1002_cam4_4481 crossref_primary_10_1056_NEJMoa1413513 crossref_primary_10_1016_S0007_4551_16_30149_7 crossref_primary_10_1158_0008_5472_CAN_13_0687 crossref_primary_10_1517_13543784_2014_924505 crossref_primary_10_1016_j_breast_2014_08_009 crossref_primary_10_1093_annonc_mdt274 crossref_primary_10_1158_1078_0432_CCR_13_1212 crossref_primary_10_1684_bdc_2012_1616 crossref_primary_10_1634_theoncologist_2012_0448 crossref_primary_10_1093_annonc_mds200 crossref_primary_10_1111_hel_12078 crossref_primary_10_1586_14737140_2015_992418 crossref_primary_10_1185_03007995_2013_807232 crossref_primary_10_4137_BCBCR_S9032 crossref_primary_10_1093_annonc_mds328 crossref_primary_10_1038_bjc_2014_356 crossref_primary_10_1093_jnci_djs636 crossref_primary_10_1016_j_ctrv_2017_06_005 crossref_primary_10_1186_s12885_017_3641_6 crossref_primary_10_1007_s11523_015_0409_2 crossref_primary_10_1016_j_ejca_2022_05_009 crossref_primary_10_1177_10781552211005530 crossref_primary_10_1158_0008_5472_CAN_21_1109 crossref_primary_10_1158_1078_0432_CCR_13_0518 crossref_primary_10_1159_000452194 crossref_primary_10_1016_j_critrevonc_2012_08_008 crossref_primary_10_1200_JCO_2012_48_4998 crossref_primary_10_2217_bmt_12_35 crossref_primary_10_1016_j_bbcan_2021_188549 crossref_primary_10_1185_03007995_2012_728132 crossref_primary_10_1080_14656566_2019_1574751 crossref_primary_10_1016_j_ctrv_2014_12_005 crossref_primary_10_1186_s12916_014_0132_3 crossref_primary_10_4161_onci_22789 crossref_primary_10_3390_ph13030039 crossref_primary_10_2217_fon_13_7 crossref_primary_10_1007_s11307_021_01688_9 crossref_primary_10_1016_j_ctrv_2013_04_002 crossref_primary_10_1007_s00259_017_3650_3 crossref_primary_10_2217_fon_15_266 crossref_primary_10_1080_2162402X_2017_1421890 crossref_primary_10_1016_j_critrevonc_2013_11_008 crossref_primary_10_1016_j_yexmp_2012_09_007 crossref_primary_10_1007_s12282_013_0446_6 crossref_primary_10_3389_fonc_2021_605941 crossref_primary_10_3390_biomedicines10102654 crossref_primary_10_1586_era_12_46 crossref_primary_10_1016_j_breast_2013_11_011 crossref_primary_10_1007_s10549_015_3292_8 crossref_primary_10_1016_j_clgc_2014_07_010 crossref_primary_10_1053_j_seminoncol_2014_07_002 crossref_primary_10_1007_s10637_017_0518_0 crossref_primary_10_1016_j_ctrv_2013_02_006 crossref_primary_10_1016_j_clbc_2013_04_001 crossref_primary_10_4161_onci_27048 crossref_primary_10_4137_CMO_S34537 crossref_primary_10_1200_JCO_2011_40_2545 crossref_primary_10_2174_0929867325666180209124052 crossref_primary_10_1007_s12094_019_02145_4 crossref_primary_10_1007_s10269_013_2348_9 crossref_primary_10_1038_s41392_024_01856_7 crossref_primary_10_1097_01_CCN_0000433811_80530_41 crossref_primary_10_1111_cpr_12266 crossref_primary_10_1016_j_breast_2015_06_002 crossref_primary_10_1016_j_breast_2016_06_024 crossref_primary_10_1016_j_pharmthera_2020_107677 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1200/JCO.2011.37.4207 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1527-7755 |
| ExternalDocumentID | 22393084 |
| Genre | Controlled Clinical Trial Comparative Study Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- .55 0R~ 18M 2WC 34G 39C 3O- 4.4 53G 5GY 5RE 8F7 AARDX AAWTL AAYEP AAYOK ABJNI ABOCM ACGFO ACGFS ACGUR ADBBV AEGXH AENEX AFFNX AIAGR ALMA_UNASSIGNED_HOLDINGS BAWUL C45 CGR CS3 CUY CVF DIK EBS ECM EIF EJD F5P F9R FBNNL FD8 GX1 H13 HZ~ IH2 KQ8 L7B LSO MJL N9A NPM O9- OK1 OVD OWW P2P QTD R1G RHI RLZ RUC SJN TEORI TR2 TWZ UDS VVN WH7 X7M YCJ YFH YQY 7X8 ABBLC |
| ID | FETCH-LOGICAL-c440t-ebae844090f01c5ed6d63d52994057585273fa6f64b0cf2ecb4acbc67d07b3ed2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 184 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000303914800009&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1527-7755 |
| IngestDate | Wed Oct 01 13:53:37 EDT 2025 Thu Apr 03 06:56:43 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 14 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c440t-ebae844090f01c5ed6d63d52994057585273fa6f64b0cf2ecb4acbc67d07b3ed2 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
| OpenAccessLink | http://hdl.handle.net/11380/737873 |
| PMID | 22393084 |
| PQID | 1011843015 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1011843015 pubmed_primary_22393084 |
| PublicationCentury | 2000 |
| PublicationDate | 2012-05-10 |
| PublicationDateYYYYMMDD | 2012-05-10 |
| PublicationDate_xml | – month: 05 year: 2012 text: 2012-05-10 day: 10 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Journal of clinical oncology |
| PublicationTitleAlternate | J Clin Oncol |
| PublicationYear | 2012 |
| References | 22393081 - J Clin Oncol. 2012 May 10;30(14):1574-6 22393085 - J Clin Oncol. 2012 May 10;30(14):1712-4 |
| References_xml | – reference: 22393081 - J Clin Oncol. 2012 May 10;30(14):1574-6 – reference: 22393085 - J Clin Oncol. 2012 May 10;30(14):1712-4 |
| SSID | ssj0014835 |
| Score | 2.504612 |
| Snippet | The combination of pertuzumab and trastuzumab resulted in a clinical benefit rate (CBR) of 50% in patients with human epidermal growth factor receptor 2 (HER2)... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1594 |
| SubjectTerms | Adult Age Factors Aged Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Breast Neoplasms - mortality Breast Neoplasms - pathology Disease Progression Disease-Free Survival Dose-Response Relationship, Drug Drug Administration Schedule Female Humans Maximum Tolerated Dose Middle Aged Neoplasm Invasiveness - pathology Neoplasm Staging Patient Selection Prognosis Prospective Studies Receptor, ErbB-2 - metabolism Risk Assessment Survival Analysis Trastuzumab Treatment Outcome |
| Title | Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/22393084 https://www.proquest.com/docview/1011843015 |
| Volume | 30 |
| WOSCitedRecordID | wos000303914800009&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1La9wwEBZpE0ovbZM-kvTBBEJOUWtrZcvbSymhoZRm60Na9rbo5bKQ2ontTdn-1P6azMjabi-FQi5GIMYSaDQaNJ--j7FDaaw0eZVxjL-KSycMNyLciKWpS3Nd6QAe__ZZTSbFdDou44VbF2GVq5gYArVrLN2R4-5OSZoET693l1ecVKOouholNO6wzRGmMgTpUtN1FUEWQWCTlFsxi8yyWKZEx3jz6eTLwN85Uq-lSNS_E8xw0Jw-vO0UH7EHMcWE94NPbLMNX--we2exiL7DjsqBrnp5DOfr11fdMRxBuSayXj5mv0vf9otfix_aAP47vtVaQtAVh77VXezldBY6-ANaB1076DAkBZx2D62fEyDeDUy10FR_G78FeltBEhbBrG8ucJQA2V3CvIZI_NoB3RjDCrIAQVsQPOnb4owv4Hvb_MT-QT4IByS0DjYEH1Bp1x4Mwe97sGTfPmFfTz-cn3zkUQuCWymTnnujfYGtcVIlqc28y10-chkepiHjLIhHrtJ5lUuT2Ep4a6S2xubKJcqMvBNP2d26qf0uA2lURiT0Qoyd9InXygmXakGvnsZaiT12sFreGe41KqDo2jeLbrZe4D32bPCR2eVACjITxCWXFHL_P6yfs_voe4IHEtgXbLPCSONfsi173c-79lVwYvxOyrMbXG0Enw |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pertuzumab+monotherapy+after+trastuzumab-based+treatment+and+subsequent+reintroduction+of+trastuzumab%3A+activity+and+tolerability+in+patients+with+advanced+human+epidermal+growth+factor+receptor+2-positive+breast+cancer&rft.jtitle=Journal+of+clinical+oncology&rft.au=Cort%C3%A9s%2C+Javier&rft.au=Fumoleau%2C+Pierre&rft.au=Bianchi%2C+Giulia+Valeria&rft.au=Petrella%2C+Teresa+M&rft.date=2012-05-10&rft.eissn=1527-7755&rft.volume=30&rft.issue=14&rft.spage=1594&rft_id=info:doi/10.1200%2FJCO.2011.37.4207&rft_id=info%3Apmid%2F22393084&rft_id=info%3Apmid%2F22393084&rft.externalDocID=22393084 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1527-7755&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1527-7755&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1527-7755&client=summon |